Semaglutide TFA (Ozempic, GLP-1 receptor agonist)-Therapeutic peptides drug benchmark for in-vivo/in-vitro study
Cat No.: GMP-Bios-peptide-004
Product Name: Semaglutide TFA
Semaglutide TFA, the trifluoroacetic acid salt form of Semaglutide. Semaglutide acts like human glucagon-like peptide-1 (GLP-1) such that it increases insulin secretion, thereby increasing sugar metabolism. Semaglutide, sold under the brand name Ozempic among others, is an anti-diabetic medicationused for the treatment of type 2 diabetes and chronic weight management.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Product Name||Semaglutide TFA|
|Biological Activity||Semaglutide acts like human glucagon-like peptide-1 (GLP-1) such that it increases insulin secretion.|
|Purity||Purity: ≥98% (HPLC)|
|Application||Therapeutic peptides drug benchmark or raw material for peptide drugs or peptide conjugation drugs discovery and development.|
|Predicted Molecular Mass||4210.63|
|Storage||Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.|